Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vera Therapeutics

< Previous 1 2 Next >
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Scheduled to Present at November Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Scheduled to Present at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback